Disclosures: Jay Luther: Nothing to Disclose, Eric Barash: Nothing to Disclose, Benjamin Grobman: Nothing to Disclose, Peter Rentzepis: Nothing to Disclose, Russell Goodman: Nothing to Disclose, Esperance Schaefer: Nothing to Disclose, Michael Butler: Nothing to Disclose, Prasanna Challa: Nothing to Disclose, Wei Zhang: Nothing to Disclose 1586 FEASIBILITY OF RADIOMICS IN PREDICTION OF OVERALL MORTALITY IN SEVERE ALCOHOLIC HEPATITIS: A PILOT STUDY Hyunseok Kim 1 Ally Hatcher 1 Vikrant Rachakonda 2 Linda Azab 1 Touseef Qureshi 1 Lixia Wang 1 Ji Hye Min 3 Polly Kirsch 1 Yee Hui Yeo 1 Walid Ayoub 4 Alexander Kuo 4 Hirsh Trivedi 1 Aarshi Vipani 1 Yun Wang 1 Stephen Pandol 1 Ju Dong Yang 4 Shelly Lu 1 Debiao Li 1 , 1 Cedars Sinai Medical Center, 2 University of Maryland, Baltimore, 3 Samsung Medical Center, 4 Cedars-Sinai Medical Center Background: Radiomics, which involves extracting large amounts of quantitative features from medical images using advanced algorithms, has shown promise in enhancing diagnostic and prognostic accuracy in various medical fields
We recognize that every patients journey is unique, and the effectiveness of GLP-1 medications can vary
Arturi F, Succurro E, Miceli S, Cloro C, Ruffo M, Maio R, et al
Wegovy is FDA-approved for long-term weight management in adults who are fat or overweight and who suffer from at least one weight-related illness, such as type 2 diabetes, high blood pressure, or high cholesterol
Interaction between CD26 and caveolin-1 results in recruitment of CARMA1 ( ca spase r ecruitment domain-containing m embrane- a ssociated guanylate kinase protein- 1 ) to APCs
The FTC declined to comment about whether or how its addressing GLP-1 claims
